Exhibit 10.9
Guardant Health, Inc.
September 16, 2018
Ian Clark
Re:    Board of Directors of Guardant Health, Inc.
Dear Ian:
This offer letter (this “Amended Letter”) amends and restates the offer letter
between you and Guardant Health, Inc. (the “Company”), dated November 30, 2016
(the “Offer Letter”), in its entirety and will provide the terms under which you
will continue to serve as a member of the Board of Directors (the “Board”) of
the Company from and after the closing of the initial public offering of the
Company’s common stock (the “IPO”).
Board Responsibilities. The Company’s current schedule includes approximately
four to six regular in-person meetings of the Board per annum, with the
possibility of additional executive session meetings, at which observers to the
Board are not included, and additional special meetings as called by the Board
from time to time. In addition to your attendance at Board meetings, we expect
to take advantage of your expertise by reaching out to you for advice and
counsel between meetings. Of course, as a member of the Board, you will be
expected to carry out your fiduciary responsibilities as a director, including
but not limited to protecting Company proprietary information from unauthorized
use or disclosure. If you would like to learn more about your fiduciary duties
as a director, I would be happy to arrange a meeting for you with our outside
counsel, Latham & Watkins LLP. We further anticipate that your service as a
member of the Board will not conflict with your service as a director of or
consultant to any other company.
Initial Stock Option. The stock options granted to you on May 31, 2017 and
November 30, 2017, covering 175,000 and 35,000 shares of Company common stock as
of the applicable grant date (on a pre-split basis), respectively (together, the
“Initial Options”), shall each remain outstanding, and each shall continue to
vest pursuant to the terms of the applicable Option Grant Notices and Agreements
between you and the Company. In addition, in the event of a Change in Control
(as defined in the Company’s 2018 Incentive Award Plan, as may be amended from
time to time), the Initial Options will vest with respect to one-hundred percent
(100%) of the shares subject thereto as of immediately prior to the Change in
Control, subject to your continued service to the Company through the closing of
such Change in Control.
Other Compensation. Effective as of the IPO, you will be eligible to receive
compensation pursuant to the Company’s Non-Employee Director Compensation
Program, as may be in effect and amended from time to time.
Business Expense Reimbursements. You will be authorized to incur on behalf and
for the benefit of, and will be reimbursed by, the Company for reasonable
documented expenses related to your service on the Board, provided such expenses
are in accordance with Company policies.
At-Will Relationship. You are free to end your relationship as a member of the
Board at any time and for any reason. In addition, your right to serve as a
member of the Board is subject to the provisions of the Company’s bylaws.
Entire Agreement. This Amended Letter will become effective upon, and only upon,
the IPO. From and after the IPO, the terms in this Amended Letter supersede any
other agreements or promises made to you by anyone, whether oral or written, and
comprise the final, complete and exclusive agreement between you and the Company
regarding your service on the Board (including the Offer Letter).
[Signature Page Follows]

--------------------------------------------------------------------------------

Assuming that you find the foregoing acceptable, we look forward to your
continued participation as a director. Please call me at 650.804.8584 if you
have any questions or comments regarding the terms described above.
Sincerely,
Guardant Health, Inc.
/s/ AmirAli Talasaz        
By: AmirAli Talasaz
Chairman of the Board
Accepted and Agreed:
/s/ Ian Clark            
Ian Clark
Date: September 16, 2018